Anthropic acquired Coefficient Bio for approximately $400 million, the company confirmed this week. Coefficient Bio is a nine-person team founded eight months ago by former researchers from Genentech's Prescient Design unit — an AI-for-drug-discovery group. [1]

The price is striking. At $400 million for nine people and eight months of existence, it is roughly $44 million per employee, paid for a company with no products, no regulatory approvals, and no revenue. That math only makes sense as a talent acquisition plus platform bet: Anthropic is buying people who understand how to apply AI to molecular biology, and a trajectory that no public entity has validated. [2]

The strategic logic is clear enough. Biology is the largest domain in which AI has not yet produced transformative commercial results. Drug discovery timelines run 10 to 15 years; AI systems that can compress those timelines by identifying candidate molecules faster represent potentially enormous economic value. Every major AI company has gestured at this market. Anthropic is now purchasing a specific capability set to compete in it. [1]

The Coefficient Bio team built what it describes as an AI platform for managing drug R&D — including clinical trial design, molecule screening, and regulatory pathway planning. That is a broad mandate. Whether it is meaningfully differentiated from what OpenAI's infrastructure can access through partnerships with Novo Nordisk and others is a question the deal doesn't answer.

What it answers is simpler: Anthropic thinks biology is next, and is willing to pay to be first. [2]

-- THEO KAPLAN, San Francisco